PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22264296-6	2012	Combining CLSI ceftriaxone and cefpodoxime critical ESBL diameters was found to be the most sensitive phenotypic screening method (sensitivity 99.2%).	cefpodoxime	31-42	EsbL	Escherichia coli	52-56	
20085420-5	2010	Of the members of the Enterobacteriaceae family, only 2 E. coli isolates were resistant to cefpodoxime, of which one produced ESBL.	cefpodoxime	91-102	EsbL	Escherichia coli	126-130	
19949753-0	2009	Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.	cefpodoxime	98-109	EsbL	Escherichia coli	0-32	
19949753-2	2009	This study explored the clinical impact of extended-spectrum beta-lactamase (ESBL) production among cefpodoxime-resistant Escherichia coli and Klebsiella pneumoniae bacteremia.	cefpodoxime	100-111	EsbL	Escherichia coli	43-75	
12532575-6	2002	Isolates resistant to cefpodoxime and aztreonam were considered as ESBL phenotype, indicating ESBL production.	cefpodoxime	22-33	EsbL	Escherichia coli	67-71	
12517841-3	2003	ESBL production was confirmed by disk diffusion assay using cefpodoxime (CPD), cefotaxime (CTX), and ceftazidime (CTZ) with and without clavulanate (CLAV).	cefpodoxime	60-71	EsbL	Escherichia coli	0-4	
12517841-3	2003	ESBL production was confirmed by disk diffusion assay using cefpodoxime (CPD), cefotaxime (CTX), and ceftazidime (CTZ) with and without clavulanate (CLAV).	cefpodoxime	73-76	EsbL	Escherichia coli	0-4	
12532575-6	2002	Isolates resistant to cefpodoxime and aztreonam were considered as ESBL phenotype, indicating ESBL production.	cefpodoxime	22-33	EsbL	Escherichia coli	94-98	
12532575-14	2002	Resistance to both cefpodoxime and aztreonam was found in 25% isolates suggesting ESBL production.	cefpodoxime	19-30	EsbL	Escherichia coli	82-86	
31949454-5	2019	Results: ESBL-producing samples had higher antibiotic resistance rates than ESBL-non-producing samples: ceftriaxone (58.8% vs. 27.3%), cefotaxime (73.5% vs. 30.3%), ceftizoxime (76.5% vs. 33.3%), cefixime (79.4% vs. 40.9%), and cefpodoxime (73.5% vs. 53%), except for carbenicillin (29.4% vs. 48.5%).	cefpodoxime	228-239	EsbL	Escherichia coli	9-13	
11146252-2	2000	We used a Vitek custom card to detect cefpodoxime MIC of--2 mg/L as a screen for extended-spectrum beta-lactamase (ESBL) production in E. coli and Klebsiella spp.	cefpodoxime	38-49	EsbL	Escherichia coli	81-113	
35451880-0	2022	In Vitro and In Vivo Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae.	cefpodoxime	85-96	EsbL	Escherichia coli	105-137	
26511749-6	2016	ESBL screening was performed on samples resistant to cefpodoxime and confirmed by double disc diffusion (Oxoid Ltd, Basingstoke, UK).	cefpodoxime	53-64	EsbL	Escherichia coli	0-4	
28368864-5	2017	All ESBL producers were resistant to ampicillin, cephalexin, cefalotin, cefpodoxime, ceftiofur, enrofloxacin, marbofloxacin, and trimethoprim/sulfamethoxazole, but were susceptible to imipenem and amoxicillin/clavulanic acid.	cefpodoxime	72-83	EsbL	Escherichia coli	4-8